What medication should be given as needed (PRN) for agitation while completing a bipolar screening, and which antipsychotic can be used as needed (PRN)?

PRN Medication for Agitation During Bipolar Screening

For acute agitation during bipolar screening, use lorazepam 2-4 mg IM/PO or haloperidol 5 mg IM as first-line monotherapy; if an antipsychotic is needed PRN, ziprasidone 20 mg IM or olanzapine 10 mg IM are preferred atypical options with lower extrapyramidal symptom risk.

First-Line Options for Undifferentiated Agitation

When managing an agitated patient during bipolar screening (before diagnosis is confirmed), the evidence supports two primary approaches 1:

Benzodiazepine Monotherapy

• Lorazepam 2-4 mg IM or PO is the most studied benzodiazepine for acute agitation
• Multiple Class II studies demonstrate benzodiazepines are at least as effective as haloperidol for controlling agitation 1
• Key advantage: No risk of extrapyramidal symptoms (EPS)
• Important caveat: Avoid in suspected anticholinergic or sympathomimetic intoxication, as these can worsen agitation 1

Conventional Antipsychotic Monotherapy

• Haloperidol 5 mg IM has the strongest evidence base among conventional antipsychotics 1
• Supported by 20 double-blind studies since 1973 1
• Risk consideration: Higher EPS rates compared to atypical antipsychotics

Atypical Antipsychotic Options (Preferred When Antipsychotic Needed)

If you specifically want an antipsychotic PRN (particularly once bipolar disorder is suspected or confirmed):

First-Line Atypical Antipsychotics

• Ziprasidone 20 mg IM: Class II evidence shows rapid and substantial reduction in acute agitation 1

  • Notable absence of movement disorders, EPS, dystonia, and hypertonia 1
  • More effective than haloperidol IM with better tolerability 1
  • Decreased mean restraint time compared to conventional therapy 1

• Olanzapine 10 mg IM: Well-tolerated atypical option 1

  • Comparable efficacy to haloperidol plus lorazepam combination 1
  • Lower EPS risk than conventional agents

Critical Safety Considerations

Route and Dose Matter

Oral formulations are significantly safer than parenteral routes - a 2025 geriatric study found intramuscular (OR 7.63) and intravenous (OR 10.17) administrations had dramatically higher adverse event rates compared to oral 2. While this was in older adults, the principle of using the lowest effective dose in the least invasive route applies universally.

Avoid These Combinations

• Do NOT combine benzodiazepine + antipsychotic in older adults - excessive adverse event risk 2
• Avoid midazolam - worst safety profile with high redosing rates and paradoxical agitation risk 2

When to Use Caution with Antipsychotics

• Medical causes of agitation: Rule out reversible causes first 1
• Anticholinergic or sympathomimetic intoxication: Antipsychotics can worsen agitation due to their anticholinergic side effects 1
• QTc prolongation: All antipsychotics prolong QTc at maximum doses, though none exceeded 500ms in studies; thioridazine had greatest effect, olanzapine the least 1

Practical Algorithm

1. Attempt verbal de-escalation first - always try non-pharmacologic management before medications 1

2. If medication needed and patient cooperative:

   • Offer oral formulation first (tablet or liquid)
   • Oral risperidone 2 mg + lorazepam 2 mg is effective for cooperative patients 1

3. If parenteral medication required:

   • For undifferentiated agitation: Lorazepam 2-4 mg IM OR haloperidol 5 mg IM
   • If antipsychotic preferred/bipolar suspected: Ziprasidone 20 mg IM (first choice) or olanzapine 10 mg IM

4. May repeat dosing: Every 20-30 minutes for IM antipsychotics, every 30-60 minutes for lorazepam 1

Common Pitfalls to Avoid

• Don't assume all agitation is psychiatric - medical causes (delirium, intoxication, withdrawal) require different management 1
• Don't use droperidol without considering FDA black box warning - though large series suggest safety, QT prolongation risk exists 1
• Don't use benzodiazepines in alcohol/drug withdrawal without recognizing they may be treating withdrawal rather than primary agitation 2
• Don't use higher doses when lower doses suffice - dose-response relationship shows increased adverse events with higher lorazepam doses 2

The evidence strongly supports starting with monotherapy rather than combination therapy for initial management, with the choice between benzodiazepine versus antipsychotic guided by clinical context, suspected diagnosis, and patient-specific factors 1.